1. Home
  2. SUZ vs BBIO Comparison

SUZ vs BBIO Comparison

Compare SUZ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Suzano S.A.

SUZ

Suzano S.A.

N/A

Current Price

$9.59

Market Cap

13.8B

ML Signal

N/A

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

N/A

Current Price

$68.53

Market Cap

15.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUZ
BBIO
Founded
1924
2015
Country
Brazil
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8B
15.3B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
SUZ
BBIO
Price
$9.59
$68.53
Analyst Decision
Strong Buy
Analyst Count
0
25
Target Price
N/A
$83.96
AVG Volume (30 Days)
4.1M
2.2M
Earning Date
05-07-2026
04-28-2026
Dividend Yield
2.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$502,076,000.00
Revenue This Year
$13.61
$88.16
Revenue Next Year
$13.19
$74.13
P/E Ratio
$5.58
N/A
Revenue Growth
N/A
126.26
52 Week Low
$8.41
$28.33
52 Week High
$11.54
$84.94

Technical Indicators

Market Signals
Indicator
SUZ
BBIO
Relative Strength Index (RSI) 36.21 46.26
Support Level $9.28 $61.95
Resistance Level $10.04 $68.71
Average True Range (ATR) 0.25 2.74
MACD -0.14 0.26
Stochastic Oscillator 16.67 37.42

Price Performance

Historical Comparison
SUZ
BBIO

About SUZ Suzano S.A.

Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: